114 results
Page 4 of 6
424B3
3eoluyd32wljbju
28 Sep 21
Prospectus supplement
9:07am
8-K
yhn04ddid91n
28 Sep 21
Entry into a Material Definitive Agreement
8:53am
424B3
11rdr sslhb39cs
13 Aug 21
Prospectus supplement
5:25pm
8-K
EX-99.1
rmuyt6af
13 Aug 21
POINT Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Update
7:00am
424B3
mckyv qxke
5 Aug 21
Prospectus supplement
4:26pm
424B3
qcs3b
9 Jun 21
Prospectus supplement
4:42pm
8-K
EX-99.1
u36j2
1 Jun 21
POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
4:32pm
8-K
3ua9t1a6wa2
1 Jun 21
POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
4:32pm
425
7ni0lx5ds1k3knaggyy
1 Jun 21
Business combination disclosure
4:30pm
425
EX-99.1
vdie89b8
1 Jun 21
Business combination disclosure
4:30pm
CORRESP
otnbenz4
3 May 21
Correspondence with SEC
12:00am
S-4/A
EX-10.19
ip16b fn10a7z
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
EX-10.10
2j6cpmcs4j
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
zn8kr 959ujz2c
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
EX-10.7
iuszrujhl62zln
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
EX-10.16
1r718ovu0yh4
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm